Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and Co BDR | B3 | Healthcare | Pharmaceuticals | R$3.87T | 63.6x | 0.79 | R$144.07 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Johnson Johnson BDR | B3 | Healthcare | Pharmaceuticals | R$1.99T | 16.7x | -0.41 | R$55.33 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novo Nordisk AS | B3 | Healthcare | Pharmaceuticals | R$1.81T | 20.5x | 1.16 | R$50.80 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AbbVie DRC | B3 | Healthcare | Pharmaceuticals | R$1.80T | 79.1x | -2.6 | R$63.72 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis AG DRC SA | B3 | Healthcare | Pharmaceuticals | R$1.25T | 18x | -1.34 | R$63.72 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca | B3 | Healthcare | Pharmaceuticals | R$1.20T | 28.3x | 1.26 | R$65.32 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck Co Inc BDR | B3 | Healthcare | Pharmaceuticals | R$1.09T | 11.5x | 0.02 | R$54 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Amgen Inc BDR | B3 | Healthcare | Pharmaceuticals | R$855.25B | 26.2x | 0.47 | R$56.43 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pfizer Inc BDR | B3 | Healthcare | Pharmaceuticals | R$745.59B | 17.2x | 0.01 | R$32.80 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Gilead Sciences DRC | B3 | Healthcare | Pharmaceuticals | R$737.78B | 22.5x | 0.02 | R$295.42 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Vertex Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$632.36B | -112.4x | 0.92 | R$617.40 | 1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bristol Myers Squibb Company BDR | B3 | Healthcare | Pharmaceuticals | R$523.49B | 17.5x | 0.09 | R$257.65 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
McKesson | B3 | Healthcare | Pharmaceuticals | R$500.82B | 28.2x | 1.85 | R$1,001 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GlaxoSmithKline | B3 | Healthcare | Pharmaceuticals | R$431.81B | 18.8x | -0.62 | R$42.75 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Zoetis | B3 | Healthcare | Pharmaceuticals | R$379.11B | 27.9x | 3.77 | R$53.70 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharmaceutical Co | B3 | Healthcare | Pharmaceuticals | R$254.81B | 63.2x | -2.36 | R$81.36 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Alnylam Pharmaceuticals DRC | B3 | Healthcare | Pharmaceuticals | R$223.64B | -123.6x | -7.19 | R$85.74 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Teva Pharmaceutical Industries DRC | B3 | Healthcare | Pharmaceuticals | R$107.46B | -15.8x | 0.09 | R$48.35 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biogen DRC | B3 | Healthcare | Pharmaceuticals | R$101.83B | 12.5x | 0.47 | R$124.32 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Incyte | B3 | Healthcare | Pharmaceuticals | R$72.57B | 621.2x | -6.37 | R$192.28 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biomarin | B3 | Healthcare | Pharmaceuticals | R$58.18B | 20.1x | 0.13 | R$150 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Hypera | B3 | Healthcare | Pharmaceuticals | R$17.49B | 21.6x | -0.41 | R$27.69 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.9% Downside | Upgrade to Pro+ | |
Hypera SA ON | B3 | Healthcare | Pharmaceuticals | R$17.49B | 21.6x | -0.41 | R$27.69 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.9% Downside | Upgrade to Pro+ | |
Blau Farmaceutica | B3 | Healthcare | Pharmaceuticals | R$2.43B | 9.1x | 0.81 | R$13.66 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.4% Upside | Upgrade to Pro+ | |
Ouro Fino Saude Animal Particip | B3 | Healthcare | Pharmaceuticals | R$1.37B | 10.7x | 0.02 | R$25.48 | 2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -15.3% Downside | Upgrade to Pro+ | |
PROFARMA ON | B3 | Healthcare | Pharmaceuticals | R$1.11B | 8.6x | 0.14 | R$9.03 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
CM Hospitalar | B3 | Healthcare | Pharmaceuticals | R$372.65M | -0.3x | 0 | R$1.18 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |